Manufacturer record
Medicef Pharma: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Medicef Pharma (Himachal Pradesh) were declared Not of Standard Quality between July 2025 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
4 records linked to Medicef Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Amoxycillin & Potassium Clavulanate Tablets IP | MFL0122Mfg 2025-03 · Exp 2027-02 | Identification - Doesn't conforms to I.P.Identification | Lucknow LabState lab | Jul 2026 |
| Amoxycillin& Potassium Clavulanate Tablets IP | MFK0983Mfg 2024-12 · Exp 2026-11 | The sample does not conform to I.P. w.r.to the tests for Identification and AssayAssay | SDTL, GuwahatiState lab | Jun 2026 |
| Amoxycillin & Potassium Clavulana Tablet I.P | MFK0722Mfg 2024-09 · Exp 2026-08 | Spurious.Spurious | SDTL, Kolkata, West BengalState lab | Sep 2025 |
| Amoxycillin & Potassium Clavulanate Tablets I.P. (Amoxyclav 625) | MFK0076Mfg 2024-02 · Exp 2026-01 | Identification and Assay of Amoxycillin and Clavulanic Acid.Assay | CDL, KolkataCDSCO lab | Jul 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.